Drug Conjugate Advances for Poor-Prognosis NSCLC

(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news

Related Links:

ConclusionPatients with stage III NSCLC and a large MTV in whom definitive RCT had a particularly good survival in the ESPATUE trial. Treatment individualization according to MTV is not supported by this study. The ESPATUE and ACRIN trials differed by the use of cisplatin-containing induction chemotherapy and an intensified radiotherapy regimen that were particularly effective in patients with large MTV disease.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Fatty acid synthase (FASN) is overexpressed in most human carcinomas, including non-small cell lung cancer (NSCLC), and contributes to poor prognosis. An increasing number of studies have highlighted the poten...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research
Conclusion: In view of the poor specificity, the current study calls for reconsideration of the universal recommendation of dedicated brain imaging (in addition to PET/CT scan) among NSCLC patients beyond stage I. PMID: 31116030 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
SummaryEntrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements inNTRK,ROS1 andALK. The combined results of two clinical trials demonstrated the efficacy of entrectinib inROS1-rearranged NSCLC. Because the development of drug resistance is inevitable, it would be helpful to determine the mechanisms of entrectinib resistance in aROS1-rearranged tumor model so that future therapeutic strategies can be developed. Here, we characterized the molecular basis of resistance in entrectinib-resistantROS1-rearranged HCC78 cells (HCC78ER cells). These cells were analyzed by next-generation sequencing and ge...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusions: MPE is common at presentation (11%) in patients with SCLC and may be associated with decreased survival. Additional studies are required to assess the treatment-adjusted survival rate in the setting of MPE.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Publication date: Available online 23 May 2019Source: Pathology - Research and PracticeAuthor(s): Shigehiro Ito, Yasuhiro Miki, Ryoko Saito, Chihiro Inoue, Yoshinori Okada, Hironobu SasanoAbstractAmyloid precursor protein (APP) is a well-known to be involved in the development of Alzheimer's disease and harbors several phosphorylation sites in its cytoplasmic domain. APP has been also proposed as one of the molecules involved in cell proliferation and invasion in several human malignancies. However, the roles of APP including its phosphorylated form (p-APP) have remained largely unexplored in non-small cell lung carcinoma ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study, we aimed to investigate the expression signatures of exosomal miRNAs and develop a serum exosome-derived miRNA panel for diagnosis of non-small cell lung cancer (NSCLC). The miR-17-92 cluster including 6 miRNAs (miR-17-5p, miR-18a-5p, miR-19a-3p, miR-19b-1-5p, miR-20a-5p and miR-92a-1-5p) was selected as potential diagnostic candidate molecule. Then, expression profiles of the candidate miRNAs were firstly analyzed in 43 pairs of serum samples from the training set by quantitative real-time PCR, and the dysregulated miRNA along with three tumor markers (carcinoembryonic antigen, CEA; cytokeratin 19 fragment,...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Authors: Spagnuolo A, Gridelli C Abstract Introduction: In recent years, immunotherapy has become an integral part of the treatment of many cancers, including non-small cell lung cancer (NSCLC). Precious therapeutic weapons impacting survival are monoclonal antibodies directed against the programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) immune checkpoint. Areas covered: Unfortunately, not all patients treated with checkpoint inhibitors have durable clinical responses. However, a better understanding of the complexity of interactions between the immune system and cancer, the latter capable of adop...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
miR‑497 suppresses malignant phenotype in non‑small cell lung cancer via targeting KDR. Oncol Rep. 2019 May 16;: Authors: Xia Y, Hu C, Lian L, Hui K, Wang L, Qiao Y, Liu L, Liang L, Jiang X Abstract The aim of the present study was to evaluate the expression of microRNA‑497 (miR‑497) in non‑small cell lung cancer (NSCLC) tissues and cell lines, and to investigate possible mechanisms associated with its regulatory role on cell behaviors. The expression level of miR‑497 was evaluated in 15 cases of NSCLC tissues and 8 adjacent normal tissues, and in 8 NSCLC cell lines, including H1975, A549, ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Kaley T, Nabors LB Abstract Meningiomas represent a full spectrum of tumors that are the most common type of brain tumor in adults. Although most are benign, recent research has shown that the recurrence rate is high, especially for WHO grades 2 and 3, and overall survival is poor for these grades. Treatment is evolving, and recently sunitinib and bevacizumab have shown promise compared with historical treatments. However, more research is needed to identify better treatments for meningiomas. Treatment of brain metastases is another evolving field. Studies suggest that stereotactic radiosurgery is preferab...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Cancer & Oncology | Hematology | Herceptin | Non-Small Cell Lung Cancer | Study